Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741941 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL28301942 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL28504067 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL10714622 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL7627118 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL28129434 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL4901016 | 0.98 | NAAA (0.64) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL31568720 | 0.94 | NAAA (0.55) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL3964880 | 0.94 | ATM (0.54) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL29214586 | 0.88 | NAAA (0.49) | NAAARAD52NPSR1FAAHDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151527-B | Process for the preparation of cyanoacetic esters | 汉高股份有限及两合公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-115151527-A | Process for the preparation of cyanoacetic esters | 汉高股份有限及两合公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-107540599-A | Aminoidan compound and its purposes for treating pain | 阿萨纳生物科技有限责任公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-103547566-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-6646135-B1 | Alpha ketoesters and alpha ketolactones to produce an alpha hydroxy carbonyl compound. | ROCHE VITAMINS INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1063224-B1 | Continuous hydrogenation process | HOFFMANN LA ROCHE (CH) | 2003-06-25 | — | — | EP | disclosed |
| EP-1200405-A1 | BENZENAMINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6350761-B1 | INHIBITORS OF THE ENZYME, FACTOR XA; | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| EP-0746306-B1 | BENZOYLACETATE ESTERS AS NON-SENSITIZING CHELATING PHOTO-PROTECTANTS | PROCTER & GAMBLE (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001009093-A1 | BENZENAMINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1063224-A1 | Continuous hydrogenation process | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-27 | — | — | EP | disclosed |
| EP-0746306-A1 | BENZOYLACETATE ESTERS AS NON-SENSITIZING CHELATING PHOTO-PROTECTANTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023585-A1 | BENZOYLACETATE ESTERS AS NON-SENSITIZING CHELATING PHOTO-PROTECTANTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | NAAA 4612/4885RAD52 4574/4885NPSR1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.